In a clinical trial of adults

XIFAXAN cut the risk of overt HE recurrence and HE-related hospitalizations in half1*

XIFAXAN significantly reduced the risk of overt HE recurrence and HE-related hospitalizations1*

Lactulose was used concomitantly by 91% of patients in both arms of the study1

Study design1,2
  • In a randomized, placebo-controlled, double-blind, multicenter, multinational, 6-month study, the efficacy of XIFAXAN 550 mg (taken orally twice a day) was evaluated in 299 adult subjects
  • Inclusion criteria: Currently in remission (Conn score of 0 or 1) from HE and ≥2 episodes of HE associated with chronic liver disease in the previous 6 months
  • Primary endpoint: Time to first breakthrough overt HE episode, defined as a marked deterioration in neurological function (an increase in Conn score to grade ≥2 or an increase in Conn score and asterixis grade of 1 each if subject entered study at grade 0)
  • Key secondary endpoint: HE-related hospitalization
XIFAXAN has a low number needed to treat (NNT)2
XIFAXAN has a low number needed to treat (NNT)
  • NNT of 14 to prevent one diabetes-related death in 10 years with metformin3,4
  • NNT of 12-26 to prevent one cardiovascular event in 10 years with statins5

The above data are not a comparison of NNT among different treatments but are intended to provide an overview of published data on NNT.

HE = hepatic encephalopathy

Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state healthcare program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full cash-paying patients. Maximum benefits and other restrictions apply. Visit or call 1-866-XIFAXAN for full eligibility criteria, terms and conditions.


XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.